Scaling-Up plant based Nanocarriers for BIOpharmaceuticals (SUNBIO)

用于生物制药的植物纳米载体的放大（SUNBIO）

• 批准号: EP/Z53304X/1
• 负责人: Munitta Muthana
• 金额: $ 19.1万
• 依托单位: University of Sheffield
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2024
• 资助国家: 英国
• 起止时间: 2024 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=EP%2FZ53304X%2F1
• 关键词: Scaling; Up; plant; based; Nanocarriers

THE CHALLENGE: Biopharmaceuticals are growing at a rate double of traditional pharma owing to the unique properties of microorganisms including their biocompatibility and technology that cannot be easily replicated in the lab. The UK needs to rapidly expand its biopharmaceutical manufacturing capacity in order to access a greater fraction of the global market and realise the economic benefits of job creation and exports."Bugs as drugs" have been seen historically to treat diseases including cancer which is inspiring the next generation of treatment options for cancer patients, particularly those with chemotherapy-resistant, recurrent, or metastatic disease. However, a major challenge for use of "bugs" including bacteria and cancer-killing viruses is they are readily recognised by the immune system and rapidly removed before they can take effect. Our team wants to overcome this challenge through our research so that we can unlock the benefits for more patients, allowing all cancer to be treated with these therapies. The full potential of these medicines can only be realised by enabling their targeted delivery to tumours within the bloodstream whilst simultaneously bypassing the body's defence systems. To do this, we have successfully developed a number of nanocarriers for cancer-killing viruses. Due to their nature, these viruses are sensitive to degradation and elimination, however our bubble-like particles not only shield them for targeted delivery, but the packaging is done in a way that maintains the viruses viability and functionality - the first time this has been shown. Synthetic alternatives (e.g. polymers) are incompatible with biological therapies due to exposure to harsh conditions (heat, solvents, pressure) during production as well as being known as highly inefficient.OBJECTIVES: Here, we focus on materials derived from natural sources (e.g. plants) that are non-toxic, biocompatible, sustainable and biodegradable. Utilising the 'safe and sustainable by design' (SSbD) framework, a voluntary approach to guide the innovation process for chemicals and advanced materials as recommended by the European Commission, we will scale-up the manufacture of our bioinspired nanocarriers to be 'clinic ready'. The scope of experiments required to optimise these systems requires high throughput microfluidics which we have developed 'in house'. Our microfluidics device can rapidly mix and produce high quality nanoparticle encapsulated viruses at large scale with the promise to outperform current commercial devices. We now want to optimise our device and consider improved mixing speed, reproducibility, productivity/scalability as well as reduced cost.BENEFIT: So far, biological therapies have not lived up to their potential due to their poor delivery in the body. Here we present a sustainable solution to scale up new modalities for the treatment of all cancers by formulating them within bioinspired nanoparticles, specifically designed to maintain the functionality of these sensitive biological agents and provide targeting capabilities. This innovative project fully aligns with the EPSRC core theme for the development of a pipeline for controllable, reproducible, and scalable production of our bioinspired NP platforms to facilitate clinical translation and unlock the power of biological therapies. This will have applications across the growing biopharma market where low therapeutic index, immunogenicity and lack of scale-up are major barriers to entry for these therapies. Whilst we use viruses as an exemplar, our platforms can be used to package any drug/agent (e.g mRNA) for wider clinical application.

挑战：生物制药的增长速度是传统制药的两倍，这是由于微生物的独特性质，包括其生物相容性和在实验室中不易复制的技术。英国需要迅速扩大其生物制药生产能力，以进入全球市场的更大份额，并实现创造就业机会和出口的经济效益。“昆虫作为药物”在历史上被视为治疗包括癌症在内的疾病，这激发了癌症患者的下一代治疗选择，特别是那些具有化疗抗性、复发性或转移性疾病的患者。然而，使用包括细菌和抗癌病毒在内的“虫子”的一个主要挑战是，它们很容易被免疫系统识别，并在它们生效之前迅速清除。我们的团队希望通过我们的研究来克服这一挑战，以便我们能够为更多患者带来益处，从而使所有癌症都能用这些疗法进行治疗。这些药物的全部潜力只能通过使其靶向输送到血流中的肿瘤，同时绕过身体的防御系统来实现。为此，我们已经成功开发了许多用于抗癌病毒的纳米载体。由于它们的性质，这些病毒对降解和消除很敏感，但是我们的气泡状颗粒不仅可以保护它们进行靶向递送，而且包装的方式可以保持病毒的活力和功能-这是第一次被证明。合成替代品（例如聚合物）与生物疗法不兼容，因为在生产过程中暴露于苛刻的条件（热、溶剂、压力），并且被认为效率极低。替代品：在这里，我们专注于来自天然来源（例如植物）的无毒、生物相容、可持续和可生物降解的材料。利用“安全和可持续的设计”（SSbD）框架，这是一种自愿性的方法，用于指导欧盟委员会推荐的化学品和先进材料的创新过程，我们将扩大我们的生物启发纳米载体的制造，以“临床准备”。优化这些系统所需的实验范围需要高通量微流体，我们已经开发了“内部”。我们的微流体设备可以快速混合并大规模生产高质量的纳米颗粒封装病毒，有望超过目前的商业设备。我们现在希望优化我们的设备，并考虑提高混合速度、再现性、生产率/可扩展性以及降低成本。好处：到目前为止，生物疗法还没有辜负他们的潜力，由于他们在体内的穷人交付。在这里，我们提出了一种可持续的解决方案，通过在生物启发纳米颗粒中配制它们来扩大治疗所有癌症的新模式，这些纳米颗粒专门设计用于保持这些敏感生物制剂的功能并提供靶向能力。这个创新项目完全符合EPSRC的核心主题，即开发一个管道，用于我们的生物启发NP平台的可控，可重复和可扩展的生产，以促进临床转化并释放生物疗法的力量。这将在不断增长的生物制药市场中得到应用，其中低治疗指数，免疫原性和缺乏规模化是这些疗法进入的主要障碍。虽然我们使用病毒作为范例，但我们的平台可用于包装任何药物/试剂（例如mRNA），以实现更广泛的临床应用。